Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Crohn's Disease Who Completed the Studies M14-431 or M14-433

X
Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Crohn's Disease Who Completed the Studies M14-431 or M14-433

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Upadacitinib (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms U-ENDURE
  • Sponsors AbbVie; AbbVie Germany
  • Most Recent Events

    • 19 Feb 2024 According to AbbVie Media Release, data from the study will be presented at the 19th Congress of European Crohn's and Colitis Organisation (ECCO) taking place in Stockholm, Sweden from February 21-24.
    • 17 Oct 2023 Results of a pooled analysis assessing effect of UPA treatment on extraintestinal manifestations in patients in induction and maintenance studies: U-EXCEL, U-EXCEED and U-ENDURE presented at the 31st United European Gastroenterology Week
    • 17 Oct 2023 Results of pooled analysis ( from studies NCT03345849,NCT03345836, and NCT03345823) assessing efficacy and safety of upadacitinib for patients with Crohns disease presented at the 31st United European Gastroenterology Week
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top